Tobam Increases Stock Holdings in Bristol Myers Squibb Company $BMY

Tobam boosted its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 17.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 95,595 shares of the biopharmaceutical company’s stock after buying an additional 14,107 shares during the quarter. Bristol Myers Squibb comprises approximately 1.6% of Tobam’s investment portfolio, making the stock its 22nd biggest holding. Tobam’s holdings in Bristol Myers Squibb were worth $4,311,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. CVA Family Office LLC increased its stake in shares of Bristol Myers Squibb by 2.6% during the 3rd quarter. CVA Family Office LLC now owns 8,959 shares of the biopharmaceutical company’s stock valued at $404,000 after acquiring an additional 223 shares during the last quarter. MSH Capital Advisors LLC grew its holdings in Bristol Myers Squibb by 2.9% in the third quarter. MSH Capital Advisors LLC now owns 8,034 shares of the biopharmaceutical company’s stock valued at $362,000 after purchasing an additional 223 shares during the period. Addison Advisors LLC increased its position in Bristol Myers Squibb by 6.2% during the third quarter. Addison Advisors LLC now owns 3,972 shares of the biopharmaceutical company’s stock worth $179,000 after purchasing an additional 232 shares during the last quarter. Mccarter Private Wealth Services LLC raised its stake in Bristol Myers Squibb by 5.0% during the third quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company’s stock worth $222,000 after purchasing an additional 235 shares during the period. Finally, Creative Financial Designs Inc. ADV boosted its holdings in shares of Bristol Myers Squibb by 26.7% in the 2nd quarter. Creative Financial Designs Inc. ADV now owns 1,123 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 237 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $60.64 on Monday. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33. The company has a market capitalization of $123.49 billion, a price-to-earnings ratio of 17.58, a PEG ratio of 0.17 and a beta of 0.29. The business has a 50-day moving average of $55.33 and a 200-day moving average of $49.48.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business’s revenue was up 1.3% on a year-over-year basis. During the same period last year, the firm posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on BMY shares. UBS Group upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $46.00 to $65.00 in a report on Wednesday, January 7th. Citigroup boosted their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Piper Sandler restated an “overweight” rating and issued a $66.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a report on Wednesday, January 28th. Scotiabank reiterated a “sector perform” rating and set a $60.00 target price (up previously from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Finally, Guggenheim restated a “buy” rating and issued a $72.00 price target (up previously from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Eight analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average price target of $59.20.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.